Micafungin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Aspergillosis
Conditions
Aspergillosis, Candidiasis
Trial Timeline
Mar 21, 2014 → Dec 21, 2014
NCT ID
NCT02646800About Micafungin
Micafungin is a approved stage product being developed by Astellas Pharma for Aspergillosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02646800. Target conditions include Aspergillosis, Candidiasis.
What happened to similar drugs?
7 of 15 similar drugs in Aspergillosis were approved
Approved (7) Terminated (5) Active (6)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
20 competing products in Aspergillosis